What we do Onyx Biotec Limited manufactures sterile pharmaceutical products like sterile water for injections and dry powder injections, acting as a contract manufacturer for major pharma firms in India and abroad. |
Founded in 2,005 |
Market share Established major player in sterile water injections with expanded capacity and WHO-GMP-certified facilities, serving top pharma clients with strong contract manufacturing presence. |
Problem solved Provides high-quality sterile pharmaceutical products filling supply needs for sterile water and dry powder injections for Indian and global markets. |
Top clients or who we serve B2B serving leading pharmaceutical companies like Aristo, Mankind, Dr Reddy's, Sun Pharma, Macleods, among others. |
Key management Harsh Mahajan (Whole-time Director), Sanjay Jain (Managing Director), plus independent directors with expertise in governance and finance. |
Our journey and innovations Founded in 2005; started sterile water ampoules production in 2010; expanded capacity in 2017-18; launched Dry Powder Injection plant in 2023 with WHO-GMP certification in 2024; IPO and NSE Emerge listing in 2024. |
Where we operate Manufacturing plants in Himachal Pradesh, India; products supplied across India and exported overseas. |
Top products or what we offer Sterile Water for Injections (FFS technology), Dry Powder Injections, Dry Syrups including Cephalosporin range under contract manufacturing. |
Top brands - |
Raw materials needed Sterile water, pharmaceutical-grade powders and excipients for injection and syrup formulations. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue is largely recurring from long-term contracts with pharmaceutical companies. |
Our industry position Significant presence in sterile water ampoules market with growing footprint in dry powder injections segment. |
Financial highlights FY2025 Revenue Rs 61.95 crore, PAT Rs 4.95 crore, revenue growth 15.26% year-over-year. |
Geographical revenue split Predominantly India with some exports abroad. |
Order book - |
Whats driving growth Market demand for injectable pharmaceuticals, capacity expansions, WHO-GMP certification, and strong client relationships. |
Our future plans Focus on increasing manufacturing capacity, enhancing product range, and leveraging WHO-GMP accreditation for exports. |
Our green promise Adopted green initiatives including recycling, paperless operations, and material segregation to reduce environmental impact. |
Our people and values Committed to talent cultivation, inclusive work culture and employee development to drive growth. |
Key challenges ahead Navigating regulatory requirements, competition, and scaling capacity to meet growing demand. |
Interesting facts IPO was oversubscribed multiple times; first WHO-GMP certification for new unit in 2024. |
Risks and strategy Mitigating regulatory and operational risks through quality certifications, governance, and continuous capacity enhancements. |
